This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

OXiGENE Provides Update On Near-Term Corporate Events

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced an update on three near-term corporate events.
  • The board of directors has voted unanimously to enact a reverse stock split with a 20:1 ratio, following authorization of the reverse split by a shareholder vote on December 21, 2010. The reverse split will be effective as of February 23, 2011. 
  • OXiGENE anticipates receiving a ruling from NASDAQ before the end of February on the Company's requests for an exception through June 13, 2011 to regain compliance with NASDAQ's listing standards and transfer the listing of its common stock to the Nasdaq Capital Market. The Company believes that the reverse stock split will represent a positive contributing factor in NASDAQ's consideration.
  • The Company also announced that the U.S. Food and Drug Administration (FDA) has granted OXiGENE's request for a meeting to discuss the results of the FACT study of ZYBRESTAT as a potential treatment for anaplastic thyroid cancer. The meeting date has been set for March 16, 2011. 

"We believe that the events reported today, as well as our recently announced warrant exchange, further support our overall goal of developing effective solutions to treat cancer and eye diseases," said OXiGENE Chief Executive Officer Peter J. Langecker, M.D., Ph.D. "We look forward to providing additional updates as key events unfold."

OXiGENE expects to provide additional updates on these and other corporate activities in its fourth quarter and full year 2010 financial results press release and on its conference call, the date of which will be announced shortly.


OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The Company's major focus is developing vascular disrupting agents that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.03 0.21%
FB $116.73 0.00%
GOOG $691.02 0.00%
TSLA $247.54 -0.07%
YHOO $36.59 0.00%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs